Prime Medicine Shares Hit 52-Week High After Dosing Begins in PM577a Trial

Dow Jones10-29
 
 

Prime Medicine shares rose after the company said the first patient has been dosed in a Phase 1/2 clinical trial of PM577a, an investigational in vivo prime editor for H1069Q-mutated Wilson disease.

The stock was 21% higher, at $5.27, on Wednesday, just off its 52-week high earlier in the session.

The biotechnology company said the milestone marks the first clinical evaluation of its liver franchise.

The company also announced that the Food and Drug Administration has granted rare pediatric disease designation to PM577 for Wilson disease.

The Phase 1/2 clinical trial is an open-label, global, first-in-human study designed to evaluate the safety, tolerability and preliminary clinical efficacy of ascending doses of PM577a in adults and adolescents with Wilson disease containing at least one p.H1069Q allele in the ATP7B gene.

The company said the study will initially enroll adults who are clinically stable on standard-of-care therapy.

 
 

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment